Skip to main content

Global Angina Pectoris Treatment Market Is Expected To Reach Usd 12,589.6 Mn By 2022

The latest market report published by Credence Research, Inc. “Global Angina Pectoris Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022,” the angina pectoris treatment market was valued at USD 7,962.8 Mn in 2015, and is expected to reach USD 12,589.6 Mn by 2022, expanding at a CAGR of 5.2% from 2016 to 2022.
Browse the full report Angina Pectoris Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at  https://www.credenceresearch.com/report/angina-pectoris-treatment-market
Market Insights
According to American College of Cardiology, Chronic angina affects over seven million North Americans and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). The market experts suggest that, various approaches have included new pharmacologic antianginal agents, interventional approaches, and therapeutic angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the first line drugs and the largest drug class segment in angina pectoris treatment market. The major factors assisting growth of beta adrenergic blockers are the efficiency, fast onset of action, accessibility to patients and high patient compliance. A few drugs in phase III of clinical trials are observed as the most potential molecules in the angina pectoris treatment. These potential molecules are such as Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as the most potential drug molecule in angina pectoris treatment in the near future. According to Tasly Pharmaceuticals, Inc. the study completion of phase III trial for Dantonic would be by December 2016. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. Thus, according to its exceptional results projected in phase II suggest that Dantonic would be the most potential pipeline drug for angina pectoris treatement.
Key Market Movements:
  • Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
  • High demand for target specific and tailored drugs for angina pectoris treatment
  • In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing
Labels:

Comments

Post a Comment

Popular posts from this blog

Global warming and Water Scarcity Ignited the Growth in Rainwater Harvesting Market

According to a new market research report published by Credence Research “ Rainwater Harvesting Market  (by Harvesting Method: Surface-based Harvesting and Roof-based Harvesting; by End-user: Residential, Commercial and Industrial) - Growth, Future Prospects, and Competitive Landscape, 2018-2026”, the rainwater harvesting market registered market value of US$ 1.35 Bn in 2017 and estimated to grow with a CAGR of 5.9% during the forecast period from 2018 to 2026. The complete report is available at  https://www.credenceresearch.com/report/rainwater-harvesting-market Market Insights: Water crises across the globe are becoming a common phenomenon with every passing day. With limited water resources, access to fresh water is shirking as a monstrous rate and the shrinking needs to be curtailed for the whole human existence. One of the most effective avenues to tackle water scarcity issues is to harvest excess water such as rainwater which otherwise washes away down the ch...
Post a Comment
Read more

Surgery Tables Market Expected To Exhibit Steady Growth During The Forecast Period

The latest market report published by Credence Research, Inc. “ Surgery Tables Market  - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global surgery tables market was valued at US$ 790.9 Mn in 2017 and expected to expand at a CAGR of 3.7% from 2018 to 2026. Browse the full report at  https://www.credenceresearch.com/report/surgery-tables-market Market Insights The global market for surgery tables is poised to grow at a steady rate during the forecast period owing growing investment in the healthcare sector across the globe due to rising volume of surgeries and growing burden of chronic diseases worldwide. Growing cases of traumatic injuries are also resulting in the rise of surgeries thereby driving the demand for surgery tables. Surgery tables with ability to position patients differently for various procedures are being developed. Development is driven considering human factors such as height of patients and bariatric and pediatri...
Post a Comment
Read more

Leadless Cardiac Pacemakers Market Is Expected To Reach US$ 269.8 Mn By 2026

The latest market report published by Credence Research, Inc. “Global  Leadless Cardiac Pacemakers Market  - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global leadless cardiac pacemakers market is expected to reach from US$ 47.1 Mn in 2017 to US$ 269.8 Mn by 2026 expanding at a CAGR of 21.9% from 2018 to 2026. Browse the full report  Leadless Cardiac Pacemakers Market  - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at   https://www.credenceresearch.com/report/leadless-cardiac-pacemakers-market Market Insights Atrial fibrillation is a medical condition in which irregular heartbeats can lead to clinical manifestations such as stroke, blood clot, and other heart complications. Many patients suffering with atrial fibrillation are under the wrong impression that it is not a serious medical condition eventually increasing the occurrence of heart failure by 5 folds. Leadless pacema...
Post a Comment
Read more